GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Kemas kini terakhir: 4 hari lalu, 12:27AM

123.91

-0.42 (-0.34%)

  • 1H -0.34%
  • 5H -1.09%
  • 1B 4.27%
  • 6B 9.65%
  • Tahun Ke Tarikh 34.86%
  • 1T 36.78%
  • 5T 103.70%
Penutupan Terdahulu 124.33
Buka 124.40
Jumlah Dagangan 5,109,934
Purata Dagangan (3B) 7,372,319
Modal Pasaran 153,748,389,888
Harga / Pendapatan (P/E TTM) 19.24
Harga / Pendapatan (P/E Ke hadapan) 14.47
Harga / Jualan (P/S) 5.51
Harga / Buku (P/B) 7.32
Julat 52 Minggu
88.57 (-28%) — 128.70 (3%)
Hasil Dividen (DY TTM) 2.55%
Margin Keuntungan 20.76%
Margin Operasi (TTM) 38.49%
EPS Cair (TTM) 4.76
Pertumbuhan Hasil Suku Tahunan (YOY) -0.30%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 24.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 130.79%
Nisbah Semasa (MRQ) 1.37
Aliran Tunai Operasi (OCF TTM) 10.37 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 9.99 B
Pulangan Atas Aset (ROA TTM) 12.14%
Pulangan Atas Ekuiti (ROE TTM) 32.65%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Gilead Sciences, Inc. Menaik Menaik

AISkor Stockmoo

0.3
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -2.5
Volatiliti Harga -0.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 0.5
Purata 0.30

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GILD 154 B 2.55% 19.24 7.32
AMGN 182 B 2.82% 26.13 19.34
AZN 282 B 1.72% 30.18 6.26
SNY 121 B 4.45% 16.36 1.41
GRFS 7 B 1.96% 14.05 0.960
BIIB 27 B - 16.61 1.42

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.10%
% Dimiliki oleh Institusi 89.79%
Julat 52 Minggu
88.57 (-28%) — 128.70 (3%)
Julat Harga Sasaran
105.00 (-15%) — 150.00 (21%)
Tinggi 150.00 (JP Morgan, 21.06%) Beli
Median 140.00 (12.99%)
Rendah 105.00 (RBC Capital, -15.26%) Pegang
Purata 135.00 (8.95%)
Jumlah 8 Beli, 1 Pegang
Harga Purata @ Panggilan 121.54
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Truist Securities 24 Nov 2025 140.00 (12.99%) Beli 125.27
03 Nov 2025 145.00 (17.02%) Beli 122.05
Needham 13 Nov 2025 140.00 (12.99%) Beli 125.20
31 Oct 2025 133.00 (7.34%) Beli 119.79
Scotiabank 13 Nov 2025 140.00 (12.99%) Beli 125.20
Cantor Fitzgerald 31 Oct 2025 135.00 (8.95%) Beli 119.79
JP Morgan 31 Oct 2025 150.00 (21.06%) Beli 119.79
16 Sep 2025 145.00 (17.02%) Beli 110.86
RBC Capital 31 Oct 2025 105.00 (-15.26%) Pegang 119.79
Wells Fargo 31 Oct 2025 145.00 (17.02%) Beli 119.79
TD Cowen 23 Oct 2025 125.00 (0.88%) Beli 120.74
Citigroup 08 Oct 2025 135.00 (8.95%) Beli 118.25
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
BLUESTONE JEFFREY - 125.84 -5,000 -629,200
KRAMER KELLY A. - 126.68 -5,611 -710,774
O'DAY DANIEL PATRICK - 125.84 -10,000 -1,258,400
Jumlah Keseluruhan Kuantiti Bersih -20,611
Jumlah Keseluruhan Nilai Bersih ($) -2,598,374
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 126.26
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
O'DAY DANIEL PATRICK Pegawai 28 Nov 2025 Jual automatik (-) 10,000 125.84 1,258,400
KRAMER KELLY A. Pengarah 28 Nov 2025 Jual automatik (-) 2,805 125.84 352,981
KRAMER KELLY A. Pengarah 28 Nov 2025 Pelaksanaan pilihan 2,805 - -
BLUESTONE JEFFREY Pengarah 28 Nov 2025 Jual (-) 5,000 125.84 629,200
BLUESTONE JEFFREY Pengarah 28 Nov 2025 Pelaksanaan pilihan 5,000 - -
KRAMER KELLY A. Pengarah 26 Nov 2025 Jual automatik (-) 2,806 127.51 357,793
KRAMER KELLY A. Pengarah 26 Nov 2025 Pelaksanaan pilihan 2,806 - -
  • 3M
Tarikh Jenis Butiran
06 Dec 2025 Pengumuman Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
06 Dec 2025 Pengumuman Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
24 Nov 2025 Pengumuman Gilead Foundation Commits Over $3 Million to Address Food Insecurity
20 Nov 2025 Pengumuman Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
18 Nov 2025 Pengumuman Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
13 Nov 2025 Pengumuman Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
07 Nov 2025 Pengumuman Gilead Provides Update on Phase 3 ASCENT-07 Study
07 Nov 2025 Pengumuman Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
04 Nov 2025 Pengumuman Gilead Sciences to Present at Upcoming Investor Conferences
03 Nov 2025 Pengumuman Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
31 Oct 2025 Pengumuman Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
30 Oct 2025 Pengumuman Gilead Sciences Announces Third Quarter 2025 Financial Results
23 Oct 2025 Pengumuman Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
19 Oct 2025 Pengumuman Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
19 Oct 2025 Pengumuman Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
15 Oct 2025 Pengumuman Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
13 Oct 2025 Pengumuman Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
09 Oct 2025 Pengumuman Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
25 Sep 2025 Pengumuman Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
Papar semua
Hasil Dividen (DY TTM) 2.55%
Purata Hasil Dividen 5T 3.80%
Nisbah Pembayaran 65.13%
Jangkaan Pembayaran Dividen Seterusnya Mar 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Dec 2025 28 Oct 2025 30 Dec 2025 0.79 Tunai
15 Sep 2025 29 Jul 2025 29 Sep 2025 0.79 Tunai
13 Jun 2025 22 Apr 2025 27 Jun 2025 0.79 Tunai
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 Tunai
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Tunai
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Tunai
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Tunai
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Tunai
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Tunai
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Tunai
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Tunai
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Tunai
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Tunai
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Tunai
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Tunai
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Tunai
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Tunai
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Tunai
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Tunai
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Tunai
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Tunai
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Tunai
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Tunai
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Tunai
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Tunai
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Tunai
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Tunai
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Tunai
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Tunai
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Tunai
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Tunai
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Tunai
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Tunai
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Tunai
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Tunai
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Tunai
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Tunai
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Tunai
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Tunai
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Tunai
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Tunai
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Tunai
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.16 4 2.55
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda